ARS Pharmaceuticals, Inc. filings document the public-company record for a biopharmaceutical issuer commercializing neffy, an epinephrine nasal spray for severe allergic reactions and anaphylaxis. The company’s 8-K filings report financial results, Regulation FD presentation updates, material agreements, product and commercialization disclosures, and legal or regulatory events involving neffy and related patent protections.
ARS Pharmaceuticals’ proxy materials describe board elections, shareholder voting matters, executive compensation, equity awards and audit oversight. Other filings identify its Nasdaq-listed common stock, capital-structure matters, credit arrangements involving ARS Pharmaceuticals Operations, Inc., and risk-related disclosures tied to product development, commercialization, intellectual property and regulatory pathways.
ARS Pharmaceuticals, Inc. President and CEO Donn Casale received a direct stock option award covering 1,036,923 Common Stock shares on October 1, 2026, with an exercise price of $4.12 per share. 25% of the shares subject to the option vest on July 7, 2027, and the remaining shares will vest monthly thereafter over three years. The option expires September 30, 2036.
ARS Pharmaceuticals, Inc. (SPRY) officer Eric Karas gave notice of a proposed sale of 100,000 common shares, with an approximate sale date of October 1, 2026. Morgan Stanley Smith Barney LLC is named as broker; the stated aggregate market value is $426,096.77. The notice also lists prior three-month sales of 100,000 shares for $431,560.00 on September 30, 2026, and 14,064 shares for $69,761.66 on September 11, 2026. It lists 100,000 shares acquired by stock option exercise from the issuer for cash on October 1, 2026.
ARS Pharmaceuticals, Inc. (SPRY) officer Eric Karas reported a proposed sale of 100,000 common shares, with an aggregate market value of $431,560.00. The securities-to-be-sold information lists a stock option exercise from the issuer, with cash shown as the payment method, dated September 30, 2026. Karas also reported selling 14,064 common shares on September 11, 2026, for $69,761.66 during the prior three months.
ARS Pharmaceuticals, Inc. (SPRY) is named as the issuer in a Form 144 filed for planned sales of its common stock by Richard Lowenthal. The notice covers an intended sale of 35,000 shares of common stock on or after September 11, 2026, following a stock option exercise for cash.
The filing also lists prior sales of ARS Pharmaceuticals common stock by Richard Lowenthal over the preceding three months, including multiple transactions in August and early September 2026 with individual trade sizes ranging from 840 to 75,000 shares.
ARS Pharmaceuticals, Inc. (SPRY) officer Eric Karas filed a notice under Rule 144 to sell up to 14,064 shares of common stock through Morgan Stanley Smith Barney. The planned sale has an aggregate market value of $69,761.66 and relates to shares acquired via the company’s Employee Stock Purchase Plan. The filing also reports that Karas sold 25,000 shares of common stock for $250,000 on June 12, 2026.
ARS Pharmaceuticals, Inc. (SPRY) received a notice that Richard Lowenthal plans to sell up to 75,000 shares of common stock under Rule 144, with Morgan Stanley Smith Barney LLC Executive Financial Services as broker. The shares are tied to a stock option exercise dated September 4, 2026, for cash settlement.
Lowenthal also reports multiple common-stock sales in the prior three months, including 50,000 shares on August 18, 2026 and another 50,000 shares on August 19, 2026, as well as smaller transactions on August 20, September 2, and September 3, 2026.
ARS Pharmaceuticals, Inc. (SPRY) has a notice from security holder Richard Lowenthal indicating an intention to sell 19,805 shares of common stock under Rule 144. The shares are to be sold on September 3, 2026, following a stock option exercise, through Morgan Stanley Smith Barney LLC.
The notice also lists prior Rule 144 sales of ARS Pharmaceuticals common stock by the same holder during the preceding three months, including transactions on August 18, 19, 20, and September 2, 2026, each with specified share amounts and dollar proceeds.
ARS Pharmaceuticals, Inc. (SPRY) reported that Chief Commercial Officer Margaret Ekins Smith received a grant of stock options for 1,001,738 shares of common stock on September 1, 2026. The options have an exercise price of $5.77 per share and expire on August 31, 2036. According to the grant terms, 25% of the shares vest on August 17, 2027, with the remaining shares vesting monthly over the following three years. These options are held directly, and no Rule 10b5-1 trading plan is reported.
ARS Pharmaceuticals, Inc. (SPRY) has a notice under Rule 144 indicating that Richard Lowenthal plans to sell 840 shares of common stock of ARS Pharmaceuticals, with the sale related to a stock option exercise dated September 2, 2026. The intended transaction is through Morgan Stanley Smith Barney LLC Executive Financial Services, with the common stock listed on NASDAQ.
During the prior three months, Richard Lowenthal reported additional sales of ARS Pharmaceuticals common stock, including 25,000 shares on August 20, 2026 for $148,160.00, 50,000 shares on August 19, 2026 for $322,345.00, and 50,000 shares on August 18, 2026 for $315,885.00.
ARS Pharmaceuticals, Inc. (SPRY) received a Form 144 notice indicating that stockholder Sarina Tanimoto plans to sell up to 45,388 shares of common stock, to be acquired via a stock option exercise and sold for cash through Morgan Stanley Smith Barney LLC. The planned sale date is listed as September 1, 2026. The notice also reports multiple prior sales of ARS Pharmaceuticals common stock by the same holder during the preceding three months.